Alzheimer's & Dementia: The Journal of the Alzheimer's Association
Volume 3, Issue 4 , Pages 283-291, October 2007

Mild cognitive impairment and cognitive impairment, no dementia: Part B, therapy

  • Fadi Massoud

      Affiliations

    • Service de Gériatrie, Centre Hospitalier de l’Université de Montréal, and Département de Médecine, Université de Montréal, Montreal, Quebec, Canada
    • Corresponding Author InformationAdditional Corresponding author. Tel.: (514) 890-8000 26769; Fax: (514) 412-7506.
  • ,
  • Sylvie Belleville

      Affiliations

    • Centre de recherche, Institut Universitaire de Gériatrie de Montréal, Montreal, Quebec, Canada
    • Department de Psychologie, Université de Montréal, Montreal, Quebec, Canada
  • ,
  • Howard Bergman

      Affiliations

    • Division of Geriatric Medicine, Department of Medicine, Sir Mortimer B. Davis-Jewish General Hospital, McGill University, Montreal, Quebec, Canada
    • Bloomfield Centre for Research in Aging, Lady Davis Institute for Medical Research, Sir Mortimer B. Davis-Jewish General Hospital, McGill University, Montreal, Quebec, Canada
  • ,
  • John Kirk

      Affiliations

    • Division of Geriatric Medicine, Department of Medicine, Sir Mortimer B. Davis-Jewish General Hospital, McGill University, Montreal, Quebec, Canada
  • ,
  • Howard Chertkow

      Affiliations

    • Centre de recherche, Institut Universitaire de Gériatrie de Montréal, Montreal, Quebec, Canada
    • Division of Geriatric Medicine, Department of Medicine, Sir Mortimer B. Davis-Jewish General Hospital, McGill University, Montreal, Quebec, Canada
    • Bloomfield Centre for Research in Aging, Lady Davis Institute for Medical Research, Sir Mortimer B. Davis-Jewish General Hospital, McGill University, Montreal, Quebec, Canada
    • Department of Neurology and Neurosurgery, McGill University, Montreal, Quebec, Canada
    • Corresponding Author InformationCorresponding author. Tel.: (514) 340-8260; Fax: (514) 340-8925.
  • ,
  • Ziad Nasreddine

      Affiliations

    • Département de médecine, service de neurologie, Hôpital Charles LeMoyne and Université de Sherbrooke, Montreal, Quebec, Canada
  • ,
  • Yves Joanette

      Affiliations

    • Centre de recherche, Institut Universitaire de Gériatrie de Montréal, Montreal, Quebec, Canada
    • Faculté de Médicine, Université de Montréal, Montreal, Quebec, Canada
  • ,
  • Morris Freedman

      Affiliations

    • Department of Medicine (Neurology), University of Toronto, and Behavioural Neurology Program, Baycrest Centre for Geriatric Care, Toronto, Ontario, Canada

published online 24 September 2007.

Abstract 

Mild cognitive impairment (MCI) and cognitive impairment, no dementia (CIND) might be the optimum stage at which to intervene with preventative therapies. This article reviews recent work on the possible treatment and presents evidence-based recommendations approved at the meeting of the Third Consensus Conference on the Diagnosis and Treatment of Dementia held in Montreal in March, 2006. A number of promising nonpharmacologic interventions have been examined. Associations exist with both cognitive and physical activity that suggest that both of these, together or separately, can delay progression to dementia. Similarly, case control studies as well as prospective long-term studies suggest a number of low toxicity interventions and supplements that might significantly impact on MCI progression; folate, B6, and B12 to lower homocysteine levels, omega-fatty acids, and anti-oxidants (fruit juices or red wine) are good examples. In selected genotypes such as individuals with APOE e4, therapy with donepezil might slow progression. The concern, however, is that none of these therapies (including cholinesterase inhibitors) have demonstrated a clinically meaningful effect with randomized, placebo-controlled studies. Just as randomized controlled studies have failed to support primary prevention of dementia by using estrogen or nonsteroidal anti-inflammatory drugs (NSAIDs), there exists the possibility that well-designed randomized controlled trials might fail to definitively demonstrate putative or promising mild cognitive impairment interventions. Pharmacologic interventions and nonpharmacologic therapies, while tantalizing, are currently for the most part insufficiently proven to allow serious consideration by physicians. Recommendation were supported for a general “healthy lifestyle” including physical exercise, healthy nutrition, smoking cessation, and mental stimulation. Close monitoring and treatment of vascular risk factors are justified and were also supported.

Keywords: MCI, CIND, Cognitive impairment, Psychosocial intervention, Cognitive intervention, Exercise

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 30.00 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S1552-5260(07)00557-2

doi:10.1016/j.jalz.2007.07.002

Alzheimer's & Dementia: The Journal of the Alzheimer's Association
Volume 3, Issue 4 , Pages 283-291, October 2007